Get the Stockscreener App
9.83
0.20%
0.02
Sutro Biopharma Inc stock is traded at $9.83, with a volume of 121.57K.
It is up +0.20% in the last 24 hours and up +21.22% over the past month.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
See More
Previous Close:
$9.81
Open:
$9.78
24h Volume:
121.57K
Relative Volume:
1.16
Market Cap:
$83.75M
Revenue:
$153.73M
Net Income/Loss:
$-106.79M
P/E Ratio:
-5.5225
EPS:
-1.78
Net Cash Flow:
$-115.93M
1W Performance:
+13.51%
1M Performance:
+21.22%
6M Performance:
+21.16%
1Y Performance:
-55.32%
1-Day Range:
$9.53
$10.10
1-Week Range:
$7.88
$10.10
52-Week Range:
$5.231
$22.30
Sutro Biopharma Inc Stock (STRO) Company Profile
Name
Sutro Biopharma Inc
Sector
Industry
Phone
650-392-8412
Address
111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Compare STRO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
STRO
Sutro Biopharma Inc
|
9.83 | 83.58M | 153.73M | -106.79M | -115.93M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Sutro Biopharma Inc Stock (STRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-16-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-17-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-14-25 | Downgrade | BofA Securities | Buy → Underperform |
| Mar-14-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Mar-14-25 | Downgrade | Wedbush | Outperform → Neutral |
| May-08-24 | Initiated | BofA Securities | Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Buy |
| Oct-06-23 | Initiated | Oppenheimer | Outperform |
| Mar-21-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Aug-18-22 | Resumed | Wells Fargo | Overweight |
| Jun-18-21 | Initiated | H.C. Wainwright | Buy |
| Dec-03-20 | Initiated | Stifel | Buy |
| Sep-02-20 | Initiated | Jefferies | Buy |
| Jul-16-20 | Initiated | Wells Fargo | Overweight |
| Jan-13-20 | Initiated | SunTrust | Buy |
| Oct-07-19 | Initiated | BTIG Research | Buy |
| Jul-18-19 | Initiated | Deutsche Bank | Buy |
| Apr-29-19 | Initiated | H.C. Wainwright | Buy |
| Oct-22-18 | Initiated | JMP Securities | Mkt Outperform |
| Oct-22-18 | Initiated | Piper Jaffray | Overweight |
| Oct-22-18 | Initiated | Wedbush | Outperform |
View All
Sutro Biopharma Inc Stock (STRO) Latest News
RBF Capital LLC Purchases New Position in Sutro Biopharma, Inc. $STRO - MarketBeat
Velan Capital Investment Management LP Acquires 2,030,000 Shares of Sutro Biopharma, Inc. $STRO - MarketBeat
Exit Recap: Will Sutro Biopharma Inc stock benefit from automationTrade Analysis Report & Low Risk Growth Stock Ideas - moha.gov.vn
Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Recommendation of “Hold” from Brokerages - Defense World
Sutro Biopharma (NASDAQ:STRO) Shares Gap DownWhat's Next? - MarketBeat
Will Sutro Biopharma Inc. (S09) stock sustain bullish trend into 20252025 Big Picture & AI Forecasted Stock Moves - Newser
Can Sutro Biopharma Inc. stock sustain institutional interestJuly 2025 Institutional & Smart Investment Allocation Tips - Newser
Is Sutro Biopharma Inc. (S09) stock a top dividend aristocrat candidatePrice Action & Weekly Market Pulse Alerts - Newser
Sutro Biopharma (NASDAQ:STRO) Shares Gap UpWhat's Next? - MarketBeat
Is Sutro Biopharma Inc. (S09) stock attractive for growth fundsPortfolio Risk Report & Weekly Watchlist of Top Performers - Newser
Sutro Biopharma doses first patients in phase 1 trial of STRO-004 - Investing.com Canada
Sutro Biopharma (NASDAQ:STRO) Receives "Neutral" Rating from Wedbush - MarketBeat
Sutro Biopharma Announces Reverse Stock Split - TipRanks
Sutro Biopharma (NASDAQ:STRO) Given Neutral Rating at Wedbush - Defense World
Sutro Biopharma Initiates Dosing in Phase 1 TF-Expressing Cancer Study - MarketScreener
Sutro Biopharma (STRO) Initiates Phase 1 Trial of STRO-004 for S - GuruFocus
Sutro Biopharma announces first cohort of patients dosed in phase 1 trial of Stro-004 - marketscreener.com
Are Smart Investors Making the Right Decision? Sutro Biopharma Inc (STRO) - setenews.com
Sutro Biopharma doses first patients in phase 1 trial of STRO-004 By Investing.com - Investing.com South Africa
Sutro Biopharma, Inc. Announces First Cohort of Patients Dosed in Phase 1 Trial of STRO-004, a Next-Generation Tissue Factor ADC, in Tissue Factor - marketscreener.com
What MACD trends signal for Sutro Biopharma Inc. (S09) stockWeekly Market Outlook & Low Volatility Stock Recommendations - Newser
Will Sutro Biopharma Inc. stock outperform value stocks2025 Market Overview & AI Enhanced Execution Alerts - Newser
Sutro Biopharma falls as it announces 1-for-10 reverse stock split - MSN
Why Sutro Biopharma Inc. stock is popular among millennials2025 Breakouts & Breakdowns & Daily Profit Maximizing Trade Tips - Newser
How Sutro Biopharma Inc. stock reacts to inflationary pressures2025 Big Picture & High Return Trade Opportunity Guides - Newser
What earnings margins imply for Sutro Biopharma Inc. (S09) stockEarnings Trend Report & Daily Technical Stock Forecast Reports - Newser
Sutro Biopharma announces 1-for-10 reverse stock split By Investing.com - au.investing.com
Sutro Biopharma stock falls after announcing 1-for-10 reverse split - Investing.com Canada
Sutro Biopharma Sets 1-for-10 Reverse Stock Split - Nasdaq
Sutro Biopharma Announces 1-for-10 Reverse Stock Split - The Manila Times
Sutro Biopharma announces 1-for-10 reverse stock split - marketscreener.com
Can Sutro Biopharma Inc. stock continue upward trendMarket Risk Analysis & Reliable Price Breakout Alerts - BỘ NỘI VỤ
Holdings of Sutro Biopharma Inc (STRO) are aligned with the stars - Setenews
Is Sutro Biopharma Inc. stock a contrarian buyQuarterly Investment Review & Risk Managed Trade Strategies - moha.gov.vn
Can Sutro Biopharma Inc. stock reach $100 price target2025 Top Decliners & Daily Profit Focused Screening - newser.com
How reliable is Sutro Biopharma Inc. (S09) stock dividend growthMarket Sentiment Summary & AI Based Trade Execution Alerts - newser.com
Why Sutro Biopharma Inc. stock attracts global investorsSwing Trade & High Conviction Investment Ideas - newser.com
Statistical indicators supporting Sutro Biopharma Inc.’s strengthWeekly Investment Summary & Consistent Income Trade Ideas - newser.com
Can Sutro Biopharma Inc. recover in the next quarterPortfolio Return Summary & Risk Adjusted Buy and Sell Alerts - newser.com
Applying big data sentiment scoring on Sutro Biopharma Inc.2025 Market WrapUp & Risk Controlled Daily Plans - newser.com
Can Sutro Biopharma Inc. (S09) stock sustain institutional flowsWeekly Profit Recap & Verified Technical Trade Signals - newser.com
Why Sutro Biopharma Inc. (S09) stock could break out in 2025 - newser.com
Sutro Biopharma Inc Stock (STRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Sutro Biopharma Inc Stock (STRO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Chow Gregory K. | CFO |
Oct 15 '25 |
Buy |
0.81 |
19,750 |
15,998 |
19,750 |
| Chung Jane | Chief Executive Officer |
Oct 15 '25 |
Buy |
0.80 |
12,500 |
10,011 |
122,850 |
| MATSUI CONNIE | Director |
Oct 15 '25 |
Buy |
0.80 |
50,000 |
39,950 |
50,000 |
| Pauling David | Chief Admin. Ofcr. & GC |
Oct 15 '25 |
Buy |
0.80 |
12,504 |
9,993 |
71,737 |
| Gerber Hans-Peter | CHIEF SCIENTIFIC OFFICER |
Sep 18 '25 |
Option Exercise |
0.00 |
37,500 |
0 |
68,249 |
| Leyman Barbara | Chief Business Officer |
Jul 08 '25 |
Option Exercise |
0.00 |
25,000 |
0 |
25,000 |
| Chung Jane | Chief Executive Officer |
Aug 09 '25 |
Option Exercise |
0.00 |
18,750 |
0 |
117,058 |
| ALBINI EDWARD C | CFO AND SECRETARY |
May 15 '25 |
Option Exercise |
0.00 |
44,719 |
0 |
176,800 |
| FITZPATRICK LINDA A | CHIEF PEOPLE & COMM. OFFICER |
May 01 '25 |
Option Exercise |
0.00 |
37,849 |
0 |
133,282 |
| Srinivasan Venkatesh | CHIEF TECH OP OFFICER |
May 01 '25 |
Option Exercise |
0.00 |
2,500 |
0 |
54,580 |
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):